Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.
Also called NCT01351636
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 300 participants
- Registry
-
NCT01351636
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01351636. Randomized; no masking; primary purpose treatment. Start 2011-04 (actual); primary completion 2018-10-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients
- Acronym
- AHOCEP
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Arotinolol Hydrochloride
- Intervention (Drug)
- Non arotinolol group
- Lead sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Record details
- Record id
cardio:ct-nct01351636- Content hash
ad173f3e87fe98a4c63754b02b845057e34c83ac193fe220ad2ffac3c612fdcb